Literature DB >> 34616034

Pembrolizumab tunes up chemotherapy in cervical cancer.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34616034     DOI： 10.1038/s41571-021-00570-5

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

Authors:  Nicoletta Colombo; Coraline Dubot; Domenica Lorusso; M Valeria Caceres; Kosei Hasegawa; Ronnie Shapira-Frommer; Krishnansu S Tewari; Pamela Salman; Edwin Hoyos Usta; Eduardo Yañez; Mahmut Gümüş; Mivael Olivera Hurtado de Mendoza; Vanessa Samouëlian; Vincent Castonguay; Alexander Arkhipov; Sarper Toker; Kan Li; Stephen M Keefe; Bradley J Monk
Journal:  N Engl J Med       Date:  2021-09-18       Impact factor: 91.245
  1 in total
  1 in total

1.  Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.

Authors:  He Huang; Cai-Ping Nie; Xiu-Feng Liu; Bin Song; Jian-Hui Yue; Jing-Xiao Xu; Jia He; Kui Li; Yan-Ling Feng; Ting Wan; Min Zheng; Yan-Na Zhang; Wei-Jun Ye; Jun-Dong Li; Yan-Fang Li; Jun-Yun Li; Xin-Ping Cao; Zhi-Min Liu; Xiao-Shi Zhang; Qing Liu; Xi Zhang; Ji-Hong Liu; Jiang Li
Journal:  J Clin Invest       Date:  2022-08-01       Impact factor: 19.456
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.